We are Healthy
U.S.

FDA Approved New Radiotracer for Glioma Diagnosis

The drug Pixclara offers a new way for adults to visualize brain tumor activity during PET scans.

Updated on Sept. 23, 2026 in Cancer

Bold flat-color editorial illustration of a brain model with an orange highlighted section and a vial, representing new medical imaging technology.
The FDA has approved Pixclara, a new radiotracer designed to improve the diagnostic visualization of glioma brain tumors during PET scans. AI Illustration. Upload story photo >

Live Poll

Should the approval process for new medical diagnostic technologies be accelerated to help patients?

The US Food and Drug Administration has approved the diagnostic agent 18F-fluoroethyl-L-tyrosine, known as Pixclara, for use in imaging gliomas. This radiotracer assists clinicians in evaluating brain tumor activity via PET scans.

Why it matters

This approval provides a new diagnostic tool that helps distinguish between growing tumors and tissue changes resulting from past cancer treatments. Such clarity is essential for clinicians managing patients with suspected brain tumors.

Researchers have published results from approximately 170 studies involving FET-PET, covering more than 11,000 patients with brain tumors. While this evidence supports diagnostic use, clinicians continue to study how Pixclara integrates with other imaging techniques.

The players

FDA

The federal agency responsible for evaluating the safety and efficacy of diagnostic drugs and medical devices in the United States.

Telix Pharmaceuticals

A biopharmaceutical company that specializes in the development of targeted radiopharmaceuticals and diagnostic imaging agents.

Forschungszentrum Jülich

A large interdisciplinary research institution in Germany that focuses on health, energy, and information technology.

The details

Pixclara is a radiotracer labeled with radioactive fluorine that is administered during positron emission tomography (PET) scans. The molecule is taken up more readily by brain tumor tissue than by healthy brain tissue, allowing for higher contrast in imaging. By mapping this uptake, doctors can better differentiate active tumor growth from post-treatment tissue changes.

Timeline

  1. The drug was originally developed at Forschungszentrum Jülich in the 1990s.

  2. The FDA granted approval for the diagnostic use of the drug on September 23, 2026.

Health Landscape

The FDA approval marks the clinical translation of the FET-PET research program at Forschungszentrum Jülich, moving the diagnostic approach from European specialized settings to the U.S. market. This adds a specific radiotracer to the standard imaging toolkit currently used for monitoring gliomas.

This development introduces a new option for brain imaging that patients with suspected gliomas can discuss with their neuro-oncologist. It is important to note that Pixclara is a diagnostic tool for imaging only and does not provide treatment for brain tumors.

The takeaway

Pixclara offers a refined way to visualize brain tumor activity, helping to clarify complex imaging results. Patients currently undergoing brain tumor surveillance should speak with their physician about whether advanced PET imaging is appropriate for their specific case.

Further reading

Learn more about the latest innovations in diagnostic procedures at Cancer.

Source note: This article includes information reported by Fz-juelich.

Live Poll

Should the approval process for new medical diagnostic technologies be accelerated to help patients?